Firmonertinib

Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation[1].

Product Specifications

CAS Number

[1869057-83-9]

Product Name Alternative

Alflutinib; Furmonertinib; AST2818

UNSPSC

12352005

Hazard Statement

H315, H319

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/firmonertinib.html

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O

Molecular Formula

C28H31F3N8O2

Molecular Weight

568.59

Precautions

H315, H319

References & Citations

[1]Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial. |[2]Alexander I. Spira, et al. FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) . Journal of Clinical Oncology. Volume 42, Number 16_suppl.